IP Library Granted Patent US 7,705,016
Granted Patent B2
US 7,705,016 · App. 10/545,056 · Granted Apr 27, 2010

Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus

Assignee: Albert Einstein College of Medicine of Yeshiva University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,705,016
App. No.
10/545,056
Granted
Apr 27, 2010
Kind
B2
Abstract

Methods of reducing food intake and glucose production in a mammal, or restoring hepatic autoregulation are provided. The methods involve increasing long-chain fatty acyl-Co-A (LC-CoA) levels in the hypothalamus, or stimulating efferent fibers in the hepatic branch of the vagus nerve. Also provided are methods of increasing food intake and glucose production in a mammal. The methods involve decreasing long-chain fatty acyl-Co-A (LC-CoA) levels in the hypothalamus of the mammal.

Claims (3)

1. A method of reducing food intake in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a small molecule capable of inhibiting carnitine palmitoyl transferase 1 (CPT1) in the brain of a mammal, wherein the pharmaceutical composition is administered in an amount and manner effective to reduce food intake in the mammal, wherein the pharmaceutical composition is administered to the brain such that the small molecule enters the hypothalamus or the pharmaceutical composition is administered such that the small molecule crosses the blood brain barrier, and wherein the small molecule capable of inhibiting CPT1 is 2-tetradecylglydate (TDGA) or (R)-N-(tetradecylcarbamoyl)-aminocarnitine.

2. The method of claim 1 , wherein the small molecule capable of inhibiting CPT1 is 2-tetradecylglydate (TDGA).

3. The method of claim 1 , wherein the small molecule capable of inhibiting CPT1 is (R)-N-(tetradecylcarbamoyl)-aminocarnitine.

Assignments (3)
GOVERNMENT INTEREST AGREEMENT Recorded Jul 23, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 036160/0860 →
CONFIRMATORY LICENSE Recorded Aug 21, 2013
From: YESHIVA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031074/0972 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2005
From: ROSSETTI, LUCIANO; OBICI, SILVANA
To: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
Reel/Frame 016845/0303 →
Continuity (2)
Provisional Application 6044713800 · Feb 13, 2003
Related Publication 20070093434A1 · Apr 26, 2007